{
    "nctId": "NCT04222426",
    "briefTitle": "89Zr-atezolizumab PET Scan and Lobular Breast Cancer",
    "officialTitle": "Can 89Zr-atezolizumab PET Scan Identify Patients With Metastatic Invasive Lobular Breast Cancer Who Will Respond to Chemotherapy-immune Checkpoint Inhibition?",
    "overallStatus": "TERMINATED",
    "conditions": "Lobular Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 1,
    "primaryOutcomeMeasure": "Change in tumor uptake between 89Zr-atezolizumab PET scan at baseline and after two carboplatin induction treatments, defined as decline or increase of standardized uptake value",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. A patient must meet the inclusion criteria of the GELATO trial\n2. Able to give written informed consent and to comply with the ImaGelato protocol\n\nExclusion Criteria:\n\n1. Contra-indication for 89Zr-atezolizumab PET scan\n2. Any approved anti-cancer therapy, including chemotherapy or hormonal therapy within \u226414 days prior to the first 89Zr-atezolizumab injection. Treatment with any other investigational agent or participation in another clinical trial with therapeutic intent within 28 days prior to the first 89Zr-atezolizumab injection.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}